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Anders Himmelmann, MD, PhD, e Steen Husted, MD, DSc, f Hugo A. Katus, MD, g Daniel Lindholm, MD, a,b
Joao Morais, MD, PhD, h Agneta Siegbahn, MD, PhD, b,i Robert F. Storey, MD, DM, j Lisa Wernroth, MSc, b and
Stefan K. James, MD, PhDa,b, on behalf of the PLATO Investigators Uppsala, Mölndal, Sweden; Cincinnati, OH;
Leeuwarden, TheNetherlands; Herning/Holstebro, Denmark;Heidelberg, Germany; Leiria, Portugal; and Sheffield, UKBackground The incremental prognostic value of admission measurements of biomarkers beyond clinical
characteristics and extent of coronary artery disease (CAD) in patients treated with primary percutaneous coronary
intervention (PPCI) for ST-elevation myocardial infarction (STEMI) is unclear.
Methods Centrally analyzed plasma for biomarker measurements was available in 5,385 of the STEMI patients
treated with PPCI in the PLATO trial. Extent of CAD was graded by operators in association with PPCI. We evaluated the
prognostic value of high-sensitivity cardiac troponin T, N-terminal pro–B-type natriuretic peptide (NT-proBNP), and growth
differentiation factor 15 (GDF-15) beyond clinical characteristics and extent of CAD using Cox proportional hazards
analyses, C-index, and net reclassification improvement (NRI). Outcomes were cardiovascular death (CVD) and
spontaneous myocardial infarction (MI).
Results Angiographic data on extent of CAD improved the prediction of CVD compared to clinical risk factors alone,
increasing the C-index from 0.760 to 0.778, total NRI of 0.31. Biomarker information provided additional prognostic value
for CVD beyond clinical risk factors and extent of CAD, C-indices ranging from 0.792 to 0.795 for all biomarkers, but with a
higher NRI for NT-proBNP. Extent of CAD and high-sensitivity cardiac troponin T were not associated with spontaneous MI. The
prediction of spontaneous MI beyond clinical characteristics and extent of CAD (C-index 0.647) was improved by both NT-
proBNP (C-index 0.663, NRI 0.22) and GDF-15 (C-index 0.652, NRI 0.05).
Conclusions Biomarker measurement on admission is feasible and provides incremental risk stratification in patients
with STEMI treated with PPCI, with NT-proBNP and GDF-15 being most valuable due to the association with both CVD and
spontaneous MI. (Am Heart J 2015;169:879-889.e7.)University, Uppsala,
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ccess article under the
-nd/4.0/).Outcomes in patients with ST-elevation myocardial
infarction (STEMI) have been substantially improved by
early reperfusion with primary percutaneous coronary
intervention (PPCI).1 However, recurrent events after the
acute phase of STEMI are common, indicating the need
for additional strategies to continue to improve the
outcome of these patients.2,3 Identification of high-risk
patients is essential for the initiation of appropriate
therapy to reduce the risk of events.1,4,5 Conventional
risk scores rely on clinical characteristics and physiolog-
ical parameters to assess the risk of mortality.4-7
Angiographic data on the extent of coronary artery
disease (CAD) may provide additional prognostic
information.8,9 Furthermore, markers of myocardial
dysfunction (N-terminal pro–B-type natriuretic peptide
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June 2015[NT-proBNP]), myocardial necrosis (high-sensitivity car-
diac troponin T [cTnT-hs]), and oxidative stress (growth
differentiation factor 15 [GDF-15]) have been shown to
improve the risk prediction over traditional risk fac-
tors.10-12 However, the individual and combined values of
these biomarkers over traditional risk factors and the
extent of CAD in patients with STEMI treated with PPCI
remain unclear.
This PLATO biomarker substudy evaluated the incre-
mental value of admission measurements of 3 biomarkers
(cTnT-hs, NT-proBNP, and GDF-15) and the angiographic
extent of CAD to clinical characteristics for the risk
stratification of patients with STEMI treated with PPCI.
Methods
Design
The present analysis is a report from the biomarker
substudy of the prospective PLATO trial (http://www.
ClinicalTrials.gov no. NCT00391872). Details of the
design and results have been published.13,14 Inclusion
criteria for the present investigation were as follows: (1)
presentation with STEMI (typical symptoms plus persis-
tent ST-elevation of ≥1 mV for ≥20 minutes not known
to be preexisting or resulting from a coexisting disorder
in ≥2 contiguous leads or new or presumed new left
bundle-branch block), (2) invasive treatment using PPCI;
and (3) availability of biomarker measurements from
samples obtained at time of randomization and full
covariate information. The study protocol was approved
by an independent ethics committee or institutional
review board, and informed consent was required before
any study procedure. The PLATO study complied with
the Declaration of Helsinki.
Objective
The present analysis sought to evaluate the prognostic
value of the extent of CAD and admission measurements
of 3 biomarkers (cTnT-hs, NT-proBNP, and GDF-15) for
the risk stratification of patients with STEMI treated with
PPCI. Angiographic extent of CAD was graded in
association with PPCI according to 3 categories: nonsig-
nificant or 1-vessel disease, 2-vessel disease, and 3-vessel
or left main disease. Significant CAD was defined as a
visual coronary stenosis N50%.
Events
The main outcomemeasures were cardiovascular death
(CVD) and spontaneous myocardial infarction (MI).
Myocardial infarction was defined in accordance with
the universal definition proposed in 2007.15 Sponta-
neous MI was defined as any MI except MI related to
percutaneous coronary intervention (PCI) or coronary
artery bypass grafting (CABG) (type 4a and type 5 MI).
The reason for this approach was the greater clinical
relevance of spontaneous MI as compared to procedur-e-related MI.16 Before the analyses, it was decided to
exclude stroke as an end point due to small number of
events and different etiology and risk associations. An
independent blinded central adjudication committee
adjudicated all end points.
Laboratory analyses
Venous blood samples were obtained at the time of
randomization, a median of 42 minutes (interquartile
range [IQR] 83 minutes) after admission. After centrifu-
gation, plasma samples were frozen in aliquots and stored
at −70°C until blinded analysis at the Uppsala Clinical
Research Center laboratory. High-sensitivity cardiac
troponin T (lot number 153 401), NT-proBNP, and
GDF-15 were determined with sandwich immunoassays
on the Cobas Analytics e601 and C501 Immunoanalyzer
(Roche Diagnostics, Penzberg, Germany) according to
the instructions of the manufacturer. The manufacturer-
provided analytical range of cTnT-hs is 3 to 10,000 ng/L,
and the limit of detection is 5 ng/L. The coefficient of
variation is b10% at 14 ng/L, the 99th percentile upper
reference limit (URL) for healthy subjects.17 For
NT-proBNP, the analytical range extends from 5 to
35,000 ng/L. The lower limit of detection is 5 ng/L, and
the lowest concentration with a coefficient of variation
b20% is 50 ng/L. The URL is defined at 300 ng/L for men
and 400 ng/L for women, corresponding to the URL in an
apparently healthy elderly population.18 The Elecsys
GDF-15 precommercial assay is reported by the manufac-
turer to have a lower detection limit of b10 ng/mL, with an
interassay coefficient of variation of 2.3% at 100 ng/mL and
1.8% at 17,200 ng/mL. The intra-assay coefficient of variation
is 0.8% at 1,100 ng/mL and 0.9% at 18,600 ng/mL. TheURL is
defined as 1,200 ng/L, corresponding to the URL in an
apparently healthy elderly population.19 The Uppsala
Clinical Research Laboratory performed twice-daily quality
checks on control samples to ensure correct calibration of
biomarker assays according to the ISO 15189 accreditation.
Statistical analyses
Analyses were performed using the PLATO safety
population, comprising patients who had received at
least 1 dose of the study drug. Characteristics were
summarized using frequencies and percentages for
categorical variables and median and 25th and 75th
percentiles for continuous variables. Trends in categor-
ical variables were evaluated using the Cochran-Armitage
trend test. The relationships between biomarkers and
extent of CAD were analyzed using Spearman's rank
order correlation, and the relationships between the
biomarkers were analyzed using Pearson product mo-
ment correlation.
Outcomes in relation to biomarkers and extent of CAD
were analyzed using Cox proportional hazards models.
The following variables were considered for the baseline
risk model: age, gender, diabetes mellitus, hypertension,
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systolic blood pressure, history of congestive heart
failure, peripheral arterial disease, cystatin C (log
transformed), previous MI, previous PCI, previous
CABG, and randomized treatment arm (ticagrelor/clopi-
dogrel). Strong correlation of hypertension, smoking
status, and previous PCI with other predictors led to the
removal of these factors from the baseline model. The
outcomes in relation to randomized treatment and
biomarker were analyzed using a model including
treatment group, biomarker quartile group, and treat-
ment by biomarker interaction as covariates.
The assumption of proportional hazards was assessed
visually using log-cumulative hazard plots and by
extending the Cox model with a time by biomarker/
CAD interaction factor. Proportional hazards were
assumed. The cumulative sums of Martingale-based
residuals indicated that a log transformation was needed
for cTnT-hs, NT-proBNP, GDF-15, and cystatin C. High-
sensitivity cardiac troponin T, NT-proBNP, and GDF-15
were evaluated as natural log-transformed continuous
variables and as quartiles. Likelihood ratio tests were
performed to evaluate whether the global model fit
improved after the addition of extent of CAD or a
biomarker. The overall C-index was used to quantify the
discriminatory ability of the multivariable models.20 The
C-index is a measure for the goodness of fit of a regression
model, a value of 0.5 indicating that a model is no better
than chance at making a correct prediction of events and
a measure of 1.0 indicating that the occurrence of events
is predicted perfectly in the study population.
Continuous (category free) net reclassification im-
provement (NRI) was calculated to quantify the degree
of correct reclassification as a result of adding extent of
CAD and biomarkers to the baseline risk model.21 Net
reclassification improvement for events constitutes the
net percentage of persons with the event correctly
assigned a higher predicted risk. Net reclassification
improvement for nonevents constitutes the net percent-
age of persons without the event of interest correctly
assigned a lower predicted risk. Total NRI is the sum of
the net percentages of persons with and without the
events of interest correctly assigned a different predicted
risk.22 Kaplan-Meier estimates of the cumulative hazard
rate were calculated and plotted.
All statistical tests were 2 tailed and performed at the 0.05
significance level. There were no adjustments for multiple
comparisons. The Clinical Research section at the Uppsala
Clinical Research center conducted the statistical analyses,
using SAS software version 9.3 (SAS Institute, Inc, Cary, NC).
The PLATO study was funded by AstraZeneca. Support
for the analysis and interpretation of results and
preparation of the manuscript was provided through
funds to the Uppsala Clinical Research Center and Duke
Clinical Research Institute as part of the Clinical Study
Agreement. Roche Diagnostics supported the research byproviding the precommercial assay of GDF-15 free
of charge.
The authors are solely responsible for the design and
conduct of this study, all analyses, the drafting and editing
of the manuscript, and its final contents.Results
In the PLATOpopulation, the safety population consisted
of the 7,471 STEMI patients who received at least 1 dose of
the study drug. Of these patients, 6,144 underwent PCI
during index hospitalization. After excluding patients with
missing biomarker measurements (n = 711) or other
covariate information (n = 48), a total of 5,385 patients
were included in the present analysis. Randomized
treatment was given for a median of 282 days (IQR 180
days). One patient in the clopidogrel arm and no patients in
the ticagrelor arm were lost to follow-up.
Baseline characteristics and event rates for the included
compared to excluded STEMI patients are shown in
online Appendix Supplementary Tables I and II. Gener-
ally, there were no major differences between included
and excluded patients, although the excluded group
showed slightly higher comorbidity, longer delay
until randomization and treatment, and marginally higher
event rates.
Extent of CAD correlated weakly with NT-proBNP
(Spearman correlation coefficient of 0.13 [95% CI
0.10-0.16, P b .001]) and GDF-15 (0.12 [95% CI
0.09-0.14, P b .001]) but not with cTnT-hs (online
Appendix Supplementary Table III). In addition, all
biomarkers correlated: cTnT-hs and NT-proBNP with a
coefficient of 0.58 (95% CI 0.57-0.60, P b .001), cTnT-hs
and GDF-15 with a coefficient of 0.16 (95% CI 0.14-0.19,
P b .001), and NT-proBNP and GDF-15 with a coefficient
of 0.34 (95% CI 0.32-0.36, P b .001).
Events
The univariable associations of extent of CAD and
biomarkers with outcome are shown in Table I and
Figures 1 and 2. Categories of CAD and quartiles of
cTnT-hs showed an increasing separation for rates of CVD
during follow-up. A more gradual increase in rates of
spontaneous MI was observed for extent of CAD but not
for cTnT-hs. The highest quartiles of NT-proBNP and
GDF-15 showed an early peak and marked separation
from lower quartiles in CVD, with a more gradual
increase in event rates for each quartile with regard to
spontaneous MI. No interactions were observed between
quartiles of biomarkers and treatment effect of ticagrelor
versus clopidogrel (online Appendix Supplementary
Table IV). The distribution of outcomes rates was similar
for all biomarkers according to delay between onset of
symptoms and randomization (online Appendix
Supplementary Figure).
Table I. Occurrence of end points during follow-up according to quartiles of biomarkers and extent of CAD
CVD Spontaneous MI
No. of events, n (%) HR (95% CI) P No. of events, n (%) HR (95% CI) P
cTnT-hs
Q1: b41 1344 16 (1.2) 1344, 42 (3.1)
Q2: 41-147 1349 33 (2.4) 2.07 (1.14-3.77) b.0001 1349, 41 (3.0) 0.99 (0.64-1.52) .7231
Q3: 148-583 1347 55 (4.1) 3.49 (2.00-6.09) 1347, 43 (3.2) 1.05 (0.68-1.60)
Q4: N583 1345 95 (7.1) 6.15 (3.62-10.45) 1345, 49 (3.6) 1.22 (0.81-1.85)
NT-proBNP
Q1: b71 1348 16 (1.2) 1348, 18 (1.3)
Q2: 71-221 1346 24 (1.8) 1.51 (0.80-2.84) b.0001 1346, 43 (3.2) 2.42 (1.39-4.19) b.0001
Q3: 222-850 1345 44 (3.3) 2.80 (1.58-4.97) 1345, 54 (4.0) 3.11 (1.82-5.30)
Q4: N850 1346 115 (8.5) 7.57 (4.49-12.77) 1346, 60 (4.5) 3.59 (2.12-6.08)
GDF-15
Q1: b1116 1346 18 (1.3) 1346, 23 (1.7)
Q2: 1116-1492 1346 26 (1.9) 1.46 (0.80-2.70) b.0001 1346, 43 (3.2) 1.90 (1.15-3.20) b.0001
Q3: 1492-2120 1347 37 (2.7) 2.06 (1.19-3.71) 1347, 47 (3.5) 2.07 (1.27-3.46)
Q4:N2120 1346 118 (8.8) 6.91 (4.33-11.74) 1346, 62 (4.6) 2.90 (1.83-4.78)
Extent of CAD
Zero/1-vessel disease 2642 54 (2.0) 2642, 66 (2.5)
2-vessel disease 1623 63 (3.9) 1.92 (1.33-2.76) b.0001 1623, 55 (3.4) 1.38 (0.96-1.97) .0010
3-vessel disease/left main 1120 82 (7.3) 3.66 (2.60-5.16) 1120, 54 (4.8) 2.00 (1.39-2.86)
Abbreviations: Q, Quartile; HR, hazard ratio. Hazard ratios represent ratios of each quartile compared to the first.
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Addition of extent of CAD to a model with clinical risk
factors substantially improved the prediction of CVD,
increasing the C-index from 0.760 to 0.778, with a total
NRI of 0.31 (Table II, Figure 3, online Appendix
Supplementary Tables V-VII). Addition of biomarkers
further improved the prediction of CVD, regardless of
extent of CAD, resulting in similar C-indices between
0.792 and 0.795, but with highest NRI for NT-proBNP. In
the subsequent model including NT-proBNP, GDF-15
added more complementary information compared to
cTnT-hs as judged by the increase in C-index. Only
NT-proBNP and GDF-15 improved the prediction of
spontaneous MI, resulting in a pronounced increase in
C-index and higher NRI for NT-proBNP, with increase
in C-index but only marginally positive NRI for GDF-15
(Table II, Figure 4).
Discussion
The present biomarker substudy in patients with STEMI
showed that cTnT-hs, NT-proBNP, and GDF-15 as well as
the angiographic extent of CAD improved the prediction
of subsequent occurrence of CVD in comparison to
clinical information alone. The predictive value of the 3
biomarkers was similar for CVD and independent of the
extent of CAD. Only NT-proBNP and GDF-15 showed
prognostic value for spontaneous MI during follow-up.
Thus, for prognostication of both CVD and spontaneous
MI after PPCI in STEMI, NT-proBNP as well as GDF-15 will
provide useful information beyond what currently is
available from clinical and angiographic data.Today, most patients with STEMI are referred immedi-
ately for PPCI, and risk stratification as a basis for
additional treatment starts when information on the
extent of CAD is available.1 The so far recommended and
tested risk scores for patients with STEMI such as the
TIMI and GRACE score are based only on clinical
characteristics.4-9 Similarly, previous evaluations of the
incremental value of biomarkers were mostly limited to
single biomarker studies and lacked CAD data.10-12,23-25
Therefore, the relative prognostic value of these markers
over the extent of CAD and each other remains unclear.
This study investigated the extent of CAD and admission
levels of 2 widely used biomarkers, cTnT-hs and
NT-proBNP, and 1 promising, but currently not generally
available, biomarker, GDF-15, in addition to clinical
information. Although the extent of CAD was confirmed
as a predictor of CVD,8,9 admission biomarkers provided
incremental prognostic information. Thus, the extent of
CAD and the levels of biomarkers carry different and
complementary information as illustrated by the poor
correlation between the level of biomarkers and the
extent of CAD. Among the established biomarkers,
NT-proBNP and cTnT-hs showed similar prognostic
value for the prediction of CVD, but only NT-proBNP
was associated with spontaneous reinfarction. Previous
studies established the predictive value of both markers
for CVD after STEMI.10,11,23-25 However, the present
study is, to our knowledge, the first to report an
independent association of admission measurements of
NT-proBNP with subsequent spontaneous reinfarction in
invasively treated STEMI patients. Natriuretic peptides
are secreted by myocardial tissue in response to both wall
Figure 1
Occurrence of CVD (left side of figure) and spontaneous MI (right side of figure) according to extent of CAD (A) and quartiles of cTnT-hs (B).
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Volume 169, Number 6stress and myocardial ischemia, possibly explaining the
association with CVD and recurrent MI.26
The novel marker GDF-15 showed similar prognostic
value for CVD compared to the established markers and
was also found to have an association with spontaneous
MI, expanding on previous findings in medically treated
STEMI patients and patients with non–ST-elevation
acute coronary syndrome.12,27 Growth differentiation
factor 15 is a member of the transforming growth
factor β superfamily, which is expressed and synthe-
sized rapidly in case of myocardial pressure/volume
overload and myocardial ischemia.28 Moreover,
GDF-15 has been associated with atherosclerotic
plaque burden in elderly individuals.29
The prognostic values of NT-proBNP and GDF-15
beyond the extent of CAD may be explained by their
relationship to vulnerability of the myocardium and/or
the vessel wall, which might be associated with a largerrisk of new plaque ruptures without underlying severe
coronary lesions as well as to a larger risk of MI when
exposed to ischemia.30 The preexisting coronary and
myocardial vulnerability may also be the reason for a
more pronounced elevation of these biomarkers in
association with the acute ischemic event.
Clinical implications
Biomarker measurement on admission is an objective
tool to aid the physician in the early recognition of
high-risk patients potentially benefiting from intensified
secondary preventive therapy, for example, early initia-
tion of angiotensin-converting enzyme inhibitors, high-
dose statin therapy, and β-blocking agents with intensi-
fied follow-up to allow strict evaluation of secondary
preventive goals such as blood pressure and lipid values
as well as up-titration of angiotensin-converting enzyme
inhibitors and β-blocking agents to evidence-based doses,
Figure 2
Occurrence of CVD (left side of figure) and spontaneousMI (right side of figure) according to quartiles of NT-proBNP (A) and quartiles of GDF-15 (B).
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patients after MI.31 Furthermore, biomarkers may be
useful to motivate early myocardial imaging or to guide
the extent of revascularization, potentially decreasing
rates of cardiac death and reinfarction in patients with
multivessel CAD.32
In this study, there was no interaction between
biomarker levels and benefit of ticagrelor, which is in
accordance with the experiences of invasively managed
non-STEMI patients with elevated cTnT-hs.33
Limitations
The generalizability of this study might be limited to
patients meeting the inclusion criteria for PLATO.
However, the patients included in PLATO seem to
represent a broad range of acute coronary syndrome
patients fairly well corresponding to the real-life situation.
There was a median of 45-minute delay until measure-
ment of biomarkers after admission. Moreover, althoughthe goal of the present study was to evaluate the use of
admission measurements of biomarkers, alternative time
points of blood sampling might provide complementary
information. Furthermore, angiographic data were not
analyzed by an independent core laboratory. The relative
prognostic value of the biomarkers and other variables
might be different in relation to longer follow-up. Finally,
additional investigations are required to explore biomarker--
guided management strategies.Conclusions
In patients with STEMI treated with PPCI, measurement
of biomarkers on admission is feasible and may be used to
identify high-risk patients potentially benefiting from
intensified management strategies. The superior prog-
nostic value of NT-proBNP concerning both CVD and
spontaneous MI and the limited influence of time delay
make NT-proBNP the most suitable currently available
Table II. Benefit of extent of CAD, cTnT-hs, NT-proBNP, and GDF-15 addition to prediction models of end points
n C-index NRI total NRI among events NRI among nonevents P value LR test
CVD 5385
Model 1⁎ 0.760 – – – –
Model 1 + extent of CAD 0.778 0.31397 0.27244 0.04153 b.0001
Model 1 + CTnT-hs 0.782 0.36913 0.17723 0.19189 b.0001
Model 1 + NT-proBNP 0.782 0.51094 0.30417 0.20677 b.0001
Model 1 + GDF-15 0.780 0.28632 0.05387 0.23246 b.0001
Model 2† 0.778 – – – –
Model 2 + CTnT-hs 0.795 0.38575 0.19803 0.18772 b.0001
Model 2 + NT-proBNP 0.792 0.47495 0.28445 0.19049 b.0001
Model 2 + GDF-15 0.795 0.30566 0.06316 0.24250 b.0001
Model 3‡ 0.792 – – – –
Model 3 + CTnT-hs 0.797 0.18349 0.06316 0.12032 .0037
Model 3 + GDF-15 0.804 0.18255 0.01770 0.16486 b.0001
Model 4§ 0.797 – – – –
Model 4 + GDF-15 0.809 0.14660 0.00879 0.13781 b.0001
Spontaneous MI 5385
Model 1⁎ 0.638 – – – –
Model 1 + extent of CAD 0.647 0.16046 0.14295 0.01751 .0704
Model 1 + CTnT-hs 0.639 0.03987 0.01224 0.02763 .6312
Model 1 + NT-proBNP 0.658 0.29251 0.17812 0.11440 .0027
Model 1 + GDF-15 0.646 0.06507 −0.10126 0.16633 .0120
Model 2† 0.647 – – – –
Model 2 + CTnT-hs 0.647 0.03348 0.00980 0.02368 .6150
Model 2 + NT-proBNP 0.663 0.21806 0.10599 0.11207 .0042
Model 2 + GDF-15 0.652 0.04869 −0.11519 0.16388 .0133
Model 3‡ 0.663 – – – –
Model 3 + CTnT-hs 0.667 0.14006 0.08020 0.05985 .1530
Model 3 + GDF-15 0.668 0.05656 −0.07530 0.13185 .0351
Model 4§ 0.667 – – – –
Model 4 + GDF-15 0.671 0.05399 −0.07480 0.12879 .0360
Abbreviation: LR, Likelihood ratio test of nested Cox proportional hazards models.
⁎Model l: age, gender, diabetes mellitus, Killip class, admission heart rate, admission systolic blood pressure, history of congestive heart failure, peripheral arterial disease, cystatin
C (log transformed), previous MI, previous PCI, previous CABG, and randomized treatment arm (ticagrelor/clopidogrel).
†Model 2: model 1 + extent of CAD.
‡Model 3: model 2 + NT-proBNP (log transformed).
§Model 4: model 3 + cTnT-hs (log transformed).
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incremental information and might be an additional
useful tool when more generally available.
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Volume 169, Number 6AppendixSupplementary Table I. Baseline characteristics
STEMI biomark
Age, median (IQR), y
Female sex, n (%) 12
Risk factors, n (%)
Habitual smoker 25
Hypertension 31
Dyslipidemia 21
Diabetes mellitus 10
History, n (%)
MI 6
PCI 4
CABG
Congestive heart failure 1
Nonhemorrhagic stroke 1
Peripheral arterial disease 2
Chronic renal disease 1
Clinical findings
Heart rate median (IQR), beat/min
Systolic blood pressure, median (IQR), mm Hg 1
Diastolic blood pressure, median (IQR), mm Hg
Killip class N2, n (%)
ECG findings at study entry, n (%)
Persistent STE of 1 mm 51
LBBB 3
Cystatin C at study entry, median (IQR), mg/L 0.75 (0
cTnT-hs at study entry, median (IQR), ng/L 147 (5
NT-proBNP at study entry, median (IQR), ng/L 221 (7
GDF-15 at study entry, median (IQR), ng/L 1492 (1
Abbreviations: ECG, Electrocardiogram; STE, ST elevation; LBBB, left bundle-branch block.er substudy (n = 5385) Excluded STEMI patients (n = 759)
59 (15) 60 (17)
19 (22.6) 167 (22.0)
26 (46.9) 377 (49.7)
01 (57.6) 437 (57.6)
32 (39.6) 262 (34.5)
23 (19.0) 158 (20.8)
25 (11.6) 98 (12.9)
28 (7.9) 66 (8.7)
99 (1.8) 22 (2.9)
12 (2.1) 10 (1.3)
29 (2.4) 29 (3.8)
19 (4.1) 23 (3.0)
50 (2.8) 20 (2.6)
75 (21) 75 (20)
31 (30) 130 (30)
80 (20) 80 (17)
42 (0.8) 12 (1.6)
85 (96.3) 719 (94.7)
21 (6.0) 59 (7.8)
.29), n = 5385 0.79 (0.26), n = 90
42), n = 5385 198 (446), n = 185
80), n = 5385 360 (926), n = 193
004), n = 5385 1501 (979), n = 214
Supplementary Table II. Treatment characteristics and events during follow-up
STEMI biomarker substudy (n = 5385) Excluded STEMI patients (n = 759)
Delay from symptom onset to randomization, median (IQR), min 259 (348) 321 (479)
Delay from admission to randomization, median (IQR), min 42 (83) 57 (120)
Delay from first ECG to PCI, median (IQR), min 97 (131) 127 (245)
Delay from admission to PCI, median (IQR), min 76 (116) 102 (183)
Underwent primary PCI within 12 h of randomization, n (%) 4812 (89.4) 637 (83.9)
Location of coronary lesion, n (%)
Left main 213 (4.0) 36 (4.7)
Left anterior descending 3626 (67.3) 512 (67.5)
Left circumflex 2158 (40.1) 321 (42.3)
Right 3213 (59.7) 430 (56.7)
Bypass graft 61 (1.1) 12 (1.6)
Extent of CAD, n (%)
Zero/1-vessel disease⁎ 2642 (49.1) 304 (42.9)
2-vessel disease 1623 (30.1) 214 (30.2)
3-vessel disease/left main 1120 (20.8) 190 (26.8)
Study drug, n (%)
Ticagrelor 2682 (49.8) 371 (48.9)
Clopidogrel 2703 (50.2) 388 (51.1)
Study treatment duration, median (IQR), d 282 (180) 329 (180)
Antithrombotic treatment in hospital
Aspirin 5310 (98.6) 728 (95.9)
Unfractioned heparin 3862 (71.7) 437 (57.6)
LMW heparin 2291 (42.5) 346 (45.6)
GP IIb/IIIa inhibitor 2287 (42.5) 323 (42.6)
Event during follow-up, n (%)
Cardiovascular death 199 (3.7) 27 (3.6)
Myocardial infarction
Procedure-related MI 68 (1.3) 12 (1.6)
Spontaneous MI 175 (3.2) 30 (4.0)
Cardiovascular death or spontaneous MI 345 (6.4) 51 (6.7)
Abbreviations: LMW, Low molecular weight; GP, glycoprotein.
⁎Nonsignificant CAD in 25 patients.
Supplementary Table III. Association between quartiles of biomarker levels and extent of CAD
Biomarker Q1 Biomarker Q2 Biomarker Q3 Biomarker Q4
Cochran-Armitage
trend test, P value
cTnT-hs, ng/L n = 1344 n = 1349 n = 1347 n = 1345
Median (min to max) 19 (2-41) 79 (41-147) 287 (148-583) 1357 (584-25747)
Extent of CAD, n (%)
Zero/1-vessel disease 663 (49.3) 664 (49.2) 655 (48.6) 660 (49.1) .8216
2-vessel disease 407 (30.3) 402 (29.8) 425 (31.6) 389 (28.9) .6775
3-vessel disease/left main 274 (20.4) 283 (21.0) 267 (19.8) 296 (22.0) .4544
NT-proBNP, ng/L n = 1348 n = 1346 n = 1345 n = 1346
Median (min to max) 39 (3-70) 128 (71-221) 428 (222-850) 1877 (851-108979)
Extent of CAD, n (%)
Zero/1-vessel disease 778 (57.7) 671 (49.9) 595 (44.2) 598 (44.4) b.0001
2-vessel disease 374 (27.7) 431 (32.0) 429 (31.9) 389 (28.9) .5492
3-vessel disease/left main 196 (14.5) 244 (18.1) 321 (23.9) 359 (26.7) b.0001
GDF-15, ng/L n = 1346 n = 1346 n = 1347 n = 1346
Median (min to max) 922 (345-1115) 1290 (1116-1492) 1730 (1492-2120) 2850 (2120-95419)
Extent of CAD, n (%)
Zero/1-vessel disease 735 (54.6) 702 (52.2) 633 (47.0) 572 (42.5) b.0001
2-vessel disease 416 (30.9) 381 (28.3) 412 (30.6) 414 (30.8) .7429
3-vessel disease/left main 195 (14.5) 263 (19.5) 302 (22.4) 360 (26.7) b.0001
Q, quartile.
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Supplementary Table IV. Interaction analyses of treatment effect (ticagrelor vs clopidogrel) according to quartiles of biomarkers
Clopidogrel Ticagrelor HR (95% CI)
P value
for interaction
Adjusted HR
(95% CI)⁎
Adjusted P value
for interaction
CVD
GDF-15 Q1 12/669 (1.8%) 6/677 (0.9%) 0.49 (0.18-1.31) .2378 0.51 (0.19-1.37) .2885
GDF-15 Q2 10/681 (1.5%) 16/665 (2.4%) 1.67 (0.76-3.67) 1.65 (0.75-3.65)
GDF-15 Q3 17/688 (2.5%) 20/659 (3.0%) 1.23 (0.64-2.35) 1.24 (0.65-2.37)
GDF-15 Q4 61/665 (9.2%) 57/681 (8.4%) 0.92 (0.64-1.32) 0.96 (0.67-1.39)
NT-proBNP Q1 6/667 (0.9%) 10/681 (1.5%) 1.64 (0.60-4.52) .4849 1.64 (0.60-4.51) .5405
NT-proBNP Q2 13/645 (2.0%) 11/701 (1.6%) 0.78 (0.35-1.75) 0.76 (0.34-1.71)
NT-proBNP Q3 20/707 (2.8%) 24/638 (3.8%) 1.34 (0.74-2.43) 1.35 (0.74-2.45)
NT-proBNP Q4 61/684 (8.9%) 54/662 (8.2%) 0.91 (0.63-1.32) 0.98 (0.68-1.42)
cTnT-hs Q1 8/671 (1.2%) 8/673 (1.2%) 1.00 (0.38-2.66) .8134 1.06 (0.40-2.84) .7064
cTnT-hs Q2 16/662 (2.4%) 17/687 (2.5%) 1.03 (0.52-2.05) 1.05 (0.53-2.08)
cTnT-hs Q3 31/690 (4.5%) 24/657 (3.7%) 0.82 (0.48-1.39) 0.80 (0.47-1.36)
cTnT-hs Q4 45/680 (6.6%) 50/665 (7.5%) 1.14 (0.76-1.70) 1.20 (0.79-1.80)
Spon MI
GDF-15 Q1 13/669 (1.9%) 10/677 (1.5%) 0.75 (0.33-1.72) .2974 0.75 (0.33-1.71) .3183
GDF-15 Q2 23/681 (3.4%) 20/665 (3.0%) 0.91 (0.50-1.66) 0.86 (0.47-1.58)
GDF-15 Q3 23/688 (3.3%) 24/659 (3.6%) 1.09 (0.61-1.93) 1.08 (0.61-1.92)
GDF-15 Q4 40/665 (6.0%) 22/681 (3.2%) 0.53 (0.31-0.89) 0.53 (0.31-0.89)
NT-proBNP Q1 10/667 (1.5%) 8/681 (1.2%) 0.79 (0.31-2.00) .3451 0.78 (0.31-1.97) .4009
NT-proBNP Q2 28/645 (4.3%) 15/701 (2.1%) 0.49 (0.26-0.92) 0.49 (0.26-0.91)
NT-proBNP Q3 28/707 (4.0%) 26/638 (4.1%) 1.04 (0.61-1.78) 0.98 (0.58-1.68)
NT-proBNP Q4 33/684 (4.8%) 27/662 (4.1%) 0.84 (0.50-1.40) 0.84 (0.50-1.40)
cTnT-hs Q1 23/671 (3.4%) 19/673 (2.8%) 0.82 (0.45-1.51) .7009 0.83 (0.45-1.53) .6615
cTnT-hs Q2 25/662 (3.8%) 16/687 (2.3%) 0.62 (0.33-1.16) 0.60 (0.32-1.13)
cTnT-hs Q3 22/690 (3.2%) 21/657 (3.2%) 1.01 (0.56-1.84) 1.00 (0.55-1.82)
cTnT-hs Q4 29/680 (4.3%) 20/665 (3.0%) 0.70 (0.39-1.23) 0.67 (0.38-1.18)
Abbreviations: HR, Hazard ratios with clopidogrel as reference; CVD, cardiovascular death; spon MI, spontaneous myocardial infarction.
⁎Adjusted for age, gender, diabetes mellitus, Killip class, admission heart rate, admission systolic blood pressure, history of congestive heart failure, peripheral arterial disease,
cystatin C (log transformed), previous MI, previous PCI, and previous CABG.
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Supplementary Table V. Multivariable Cox regression model cTnT-hs for outcome measures
Added biomarker cTnT-hs No. of patients CVD HR(95% CI) Spon MI HR(95% CI)
Unadjusted: Q 1 1344
Unadjusted: Q 2 1349 2.07 (1.16-3.87) 0.99 (0.64-1.52)
Unadjusted: Q 3 1347 3.49 (2.05-6.29) 1.05 (0.68-1.61)
Unadjusted: Q 4 1345 6.15 (3.73-10.85) 1.22 (0.81-1.85)
Unadjusted: Cont 5385 1.91 (1.66-2.22) 1.09 (0.94-1.26)
Model 1 + biom: Q 1 1344
Model 1 + biom: Q 2 1349 1.75 (0.98-3.27) 0.95 (0.61-1.47)
Model 1 + biom: Q 3 1347 2.57 (1.50-4.65) 0.94 (0.61-1.46)
Model 1 + biom: Q 4 1345 3.67 (2.20-6.53) 1.07 (0.70-1.63)
Model 1 + biom: Cont 5385 1.61 (1.38-1.88) 1.04 (0.89-1.21)
Model 2 + biom: Q 1 1344
Model 2 + biom: Q 2 1349 1.76 (0.98-3.29) 0.95 (0.61-1.46)
Model 2 + biom: Q 3 1347 2.61 (1.52-4.72) 0.95 (0.62-1.46)
Model 2 + biom: Q 4 1345 3.71 (2.22-6.60) 1.07 (0.70-1.65)
Model 2 + biom: Cont 5385 1.61 (1.38-1.87) 1.04 (0.89-1.21)
Model 3 + biom: Q 1 1344
Model 3 + biom: Q 2 1349 1.67 (0.92-3.13) 0.84 (0.54-1.30)
Model 3 + biom: Q 3 1347 2.12 (1.20-3.95) 0.71 (0.45-1.13)
Model 3 + biom: Q 4 1345 2.53 (1.41-4.76) 0.73 (0.45-1.21)
Model 3 + biom: Cont 5385 1.32 (1.09-1.60) 0.87 (0.72-1.05)
Model 4 + biom: Q 1 1344
Model 4 + biom: Q 2 1349 1.65 (0.92-3.11) 0.84 (0.54-1.31)
Model 4 + biom: Q 3 1347 2.20 (1.24-4.10) 0.74 (0.47-1.17)
Model 4 + biom: Q 4 1345 2.43 (1.35-4.61) 0.73 (0.45-1.20)
Model 4 + biom: Cont 5385 1.28 (1.07-1.55) 0.87 (0.72-1.05)
SD biom: 1.76
Abbreviations: Biom, Biomarker; Cont, continuous. Continuous analysis HR: per SD of logarithm of biomarker. Quartile analysis: HRs represent ratios of each quartile compared to the first.
Model l: age, gender, diabetes mellitus, Killip class, admission heart rate, admission systolic blood pressure, history of congestive heart failure, peripheral arterial disease, cystatin C
(log transformed), previous MI, previous PCI, previous CABG, randomized treatment arm (ticagrelor/clopidogrel).
Model 2: model 1 + extent of CAD.
Model 3: model 2 + NT proBNP.
Model 4: model 3 + GDF-15.
889.e4 Velders et al
American Heart Journal
June 2015
Supplementary Table VI. Multivariable Cox regression model NT-proBNP for outcome measures
Added biomarker NT-proBNP No. of patients CVD HR(95% CI) Spon MI HR(95% CI)
Unadjusted: Q 1 1348
Unadjusted: Q 2 1346 1.51 (0.81-2.89) 2.42 (1.42-4.30)
Unadjusted: Q 3 1345 2.80 (1.62-5.12) 3.11 (1.86-5.45)
Unadjusted: Q 4 1346 7.57 (4.63-13.27) 3.59 (2.17-6.26)
Unadjusted: Cont 5385 2.50 (2.16-2.90) 1.49 (1.29-1.73)
Model 1 + biom: Q 1 1348
Model 1 + biom: Q 2 1346 1.21 (0.64-2.33) 2.10 (1.23-3.76)
Model 1 + biom: Q 3 1345 1.98 (1.13-3.65) 2.47 (1.46-4.39)
Model 1 + biom: Q 4 1346 3.46 (2.03-6.26) 2.48 (1.44-4.48)
Model 1 + biom: Cont 5385 1.75 (1.48-2.07) 1.30 (1.10-1.55)
Model 2 + biom: Q 1 1348
Model 2 + biom: Q 2 1346 1.16 (0.62-2.23) 2.07 (1.21-3.70)
Model 2 + biom: Q 3 1345 1.81 (1.03-3.34) 2.39 (1.41-4.24)
Model 2 + biom: Q 4 1346 3.22 (1.89-5.84) 2.42 (1.40-4.37)
Model 2 + biom: Cont 5385 1.71 (1.45-2.03) 1.29 (1.08-1.54)
Model 3 + biom: Q 1 1348
Model 3 + biom: Q 2 1346 0.99 (0.52-1.92) 2.21 (1.28-3.97)
Model 3 + biom: Q 3 1345 1.32 (0.73-2.51) 2.73 (1.56-4.98)
Model 3 + biom: Q 4 1346 1.98 (1.07-3.83) 2.93 (1.57-5.65)
Model 3 + biom: Cont 5385 1.43 (1.17-1.76) 1.41 (1.14-1.75)
Model 4 + biom: Q 1 1348
Model 4 + biom: Q 2 1346 0.97 (0.51-1.88) 2.17 (1.26-3.90)
Model 4 + biom: Q 3 1345 1.29 (0.71-2.46) 2.66 (1.52-4.85)
Model 4 + biom: Q 4 1346 1.81 (0.98-3.53) 2.78 (1.48-5.37)
Model 4 + biom: Cont 5385 1.35 (1.10-1.66) 1.37 (1.11-1.70)
SD biom: 1.64
Abbreviations as in Table V.
Continuous analysis HR: per SD of logarithm of biomarker. Quartile analysis: HRs represent ratios of each quartile compared to the first.
Model l: age, gender, diabetes mellitus, Killip class, admission heart rate, admission systolic blood pressure, history of congestive heart failure, peripheral arterial disease, cystatin C
(log transformed), previous MI, previous PCI, previous CABG, randomized treatment arm (ticagrelor/clopidogrel).
Model 2: model 1 + extent of CAD.
Model 3: model 2 + cTnT-hs.
Model 4: model 3 + GDF-15.
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Supplementary Table VII. Multivariable Cox regression model GDF-15 for outcome measures
Added biomarker GDF-15 No. of patients CVD HR(95% CI) Spon MI HR(95% CI)
Unadjusted: Q 1 1346
Unadjusted: Q 2 1346 1.46 (0.80-2.70) 1.90 (1.15-3.20)
Unadjusted: Q 3 1347 2.06 (1.19-3.71) 2.07 (1.27-3.46)
Unadjusted: Q 4 1346 6.91 (4.33-11.74) 2.90 (1.83-4.78)
Unadjusted: Cont 5385 1.82 (1.67-1.96) 1.36 (1.20-1.53)
Model 1 + biom: Q 1 1346
Model 1 + biom: Q 2 1346 1.14 (0.63-2.13) 1.73 (1.05-2.94)
Model 1 + biom: Q 3 1347 1.27 (0.72-2.32) 1.69 (1.02-2.88)
Model 1 + biom: Q 4 1346 2.77 (1.64-4.94) 2.06 (1.22-3.58)
Model 1 + biom: Cont 5385 1.52 (1.34-1.70) 1.23 (1.05-1.43)
Model 2 + biom: Q 1 1346
Model 2 + biom: Q 2 1346 1.11 (0.61-2.07) 1.72 (1.04-2.92)
Model 2 + biom: Q 3 1347 1.20 (0.68-2.19) 1.67 (1.00-2.84)
Model 2 + biom: Q 4 1346 2.63 (1.55-4.69) 2.03 (1.20-3.53)
Model 2 + biom: Cont 5385 1.52 (1.35-1.71) 1.23 (1.05-1.43)
Model 3 + biom: Q 1 1346
Model 3 + biom: Q 2 1346 1.05 (0.58-1.96) 1.68 (1.01-2.84)
Model 3 + biom: Q 3 1347 1.10 (0.62-2.01) 1.60 (0.96-2.73)
Model 3 + biom: Q 4 1346 2.25 (1.32-4.04) 1.94 (1.14-3.38)
Model 3 + biom: Cont 5385 1.43 (1.26-1.62) 1.20 (1.01-1.40)
Model 4 + biom: Q 1 1346
Model 4 + biom: Q 2 1346 1.07 (0.59-1.99) 1.66 (1.01-2.83)
Model 4 + biom: Q 3 1347 1.12 (0.63-2.04) 1.60 (0.96-2.73)
Model 4 + biom: Q 4 1346 2.27 (1.32-4.09) 1.91 (1.12-3.33)
Model 4 + biom: Cont 5385 1.42 (1.25-1.61) 1.19 (1.01-1.39)
SD biom: 0.54
Abbreviations as in Table V.
Continuous analysis HR: per SD of logarithm of biomarker. Quartile analysis: HRs represent ratios of each quartile compared to the first.
Model l: age, gender, diabetes mellitus, Killip class, admission heart rate, admission systolic blood pressure, history of congestive heart failure, peripheral arterial disease, cystatin C
(log transformed), previous MI, previous PCI, previous CABG, randomized treatment arm (ticagrelor/clopidogrel).
Model 2: model 1 + extent of CAD.
Model 3: model 2 + NT-proBNP.
Model 4: model 3 + cTnT-hs.
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Supplementary Figure
Occurrence of CVD for quartiles of cTnT-hs (A), quartiles of NT-proBNP (B), and quartiles of GDF-15 (C) stratified according to time between onset
of symptoms and randomization.
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